Regarding HCC, a novel anti-HER2 biparatopic tetravalent antibody exhibits enhanced antitumor efficacy through multiple mechanisms, including inducing HER2 clustering, internalization, and degradation [288–292]. Here, ERBB2 is linked to hepatocellular carcinoma.